• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Brought to you by:

Cell & Gene Therapy

Explore the latest news and insight around cell and gene therapy, including new technology and information on treatments in this growing field. See how pharma is leveraging gene therapy and cell therapy to prevent and treat disease.

Brought to you by:
0
Closeup of blue eye on black background
Biotech

Lilly buys cash-strapped Adverum for eye disease gene therapy

Just as Adverum’s cash reserves were running dry, Eli Lilly has swooped in to buy the biotech and its phase 3-stage eye disease gene therapy.
James Waldron Oct 24, 2025 9:25am
Make a delay and accumulation of outstanding tasks Full stop

Regeneron does 180 on 2seventy lymphoma CAR-T

Oct 23, 2025 10:57am
End of road sign on street

Galapagos to wind down cell therapy unit, threatening 365 jobs

Oct 21, 2025 9:30am
Silhouette of Businessman Entering Lit Door Passage in Darkness

Astellas turns down option to license Taysha gene therapy—again

Oct 17, 2025 10:50am
kite

Kite puts $1.64B on the line for Pregene's in vivo CAR-Ts

Oct 16, 2025 4:56pm
american tariffs and US flag on yellow caution line i

'Let that one go': Nkarta CEO urges US gov to drop China regs

Oct 16, 2025 2:00pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings